1-7 of 7
Michael Williams
Close
Sort by
Journal Articles

Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011

Clinical Trials & Observations
Peter W. Collins, Benedict P. Palmer, Elizabeth A. Chalmers, Daniel P. Hart, Ri Liesner, Savita Rangarajan, Katherine Talks, Michael Williams, Charles R. M. Hay
Journal: Blood
Blood (2014) 124 (23): 3389–3397.
https://doi.org/10.1182/blood-2014-07-580498
Published: 2014
Journal Articles

Pharmacokinetic Characterisation Of Recombinant FXIII Across Age Groups In Patients With FXIII Subunit A Congenital Deficiency

Brigitte Brand-Staufer, MD, Manuel Carção, MD, BSC, Bryce A. Kerlin, MD, Diane Nugent, MD, Andrew Will, Michael Williams, Anders Rosholm, MSc, PhD, Mia Sandberg Lundblad
Journal: Blood
Blood (2013) 122 (21): 3613.
https://doi.org/10.1182/blood.V122.21.3613.3613
Published: 2013
Journal Articles

Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom

Brief Report
Charles R.M. Hay, Ben Palmer, Elizabeth Chalmers, Ri Liesner, Rhona Maclean, Savita Rangarajan, Michael Williams, Peter W. Collins, on behalf of United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO)
Journal: Blood
Blood (2011) 117 (23): 6367–6370.
https://doi.org/10.1182/blood-2010-09-308668
Published: 2011
Journal Articles

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Nathan Fowler, Brad S Kahl, Peter Rosen, Jeffrey Matous, Amanda Cashen, Samuel Jacobs, Jeffrey Letzer, Bipinkumar Amin, Michael Williams, Maureen Ross, Sonali Smith, Alfred Saleh, Hongliang Shi, Sudha Parasuraman, Bruce D. Cheson
Journal: Blood
Blood (2009) 114 (22): 933.
https://doi.org/10.1182/blood.V114.22.933.933
Published: 2009
Journal Articles

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

Roberto Piva, Bruce Ruggeri, Michael Williams, Giulia Costa, Ilaria Tamagno, Dario Ferrero, Valentina Giai, Marta Coscia, Silvia Peola, Massimo Massaia, Gabriella Pezzoni, Cecilia Allievi, Nicoletta Pescalli, Mara Cassin, Stefano di Giovine, Paola Nicoli, Paola de Feudis, Ivan Strepponi, Ilaria Roato, Riccardo Ferracini, Benedetta Bussolati, Giovanni Camussi, Susan Jones-Bolin, Kathryn Hunter, Hugh Zhao, Antonino Neri, Antonio Palumbo, Celia Berkers, Huib Ovaa, Alberto Bernareggi, Giorgio Inghirami
Journal: Blood
Blood (2008) 111 (5): 2765–2775.
https://doi.org/10.1182/blood-2007-07-100651
Published: 2008
Journal Articles

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, PhD, Michael Williams, MD, Rafat Abonour, MD, David Siegel, MD, Philip Greipp, MD
Journal: Blood
Blood (2007) 110 (11): 74.
https://doi.org/10.1182/blood.V110.11.74.74
Published: 2007
Journal Articles

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV

Clinical Trials & Observations
Sarah C. Darby, Sau Wan Kan, Rosemary J. Spooner, Paul L. F. Giangrande, Frank G. H. Hill, Charles R. M. Hay, Christine A. Lee, Christopher A. Ludlam, Michael Williams
Journal: Blood
Blood (2007) 110 (3): 815–825.
https://doi.org/10.1182/blood-2006-10-050435
Published: 2007
Includes: Supplemental data